What is Akynzeo?
Akynzeo is a combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It is comprised of netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-5-HT3 receptor antagonist [1][2]. This dual mechanism targets different pathways involved in triggering nausea and vomiting during chemotherapy [1].
How is Akynzeo Administered?
Akynzeo is administered as a single oral capsule [1]. The netupitant component is typically given one hour prior to the start of chemotherapy, while the palonosetron component is administered 30 minutes before the start of chemotherapy [1].
What are the Benefits of Akynzeo?
Akynzeo offers a dual mechanism of action, addressing both acute and delayed phases of CINV [1]. By combining two antiemetic classes, it aims to provide comprehensive protection against nausea and vomiting associated with chemotherapy [1][2].
When Does Akynzeo's Patent Protection End?
Information regarding the specific patent expiry dates for Akynzeo is best accessed through specialized drug patent databases. Websites like DrugPatentWatch.com provide detailed timelines for patent protection and exclusivity periods for various medications [3].
Are There Alternatives to Akynzeo for CINV?
Yes, other medications are available to manage CINV. These include other NK1 receptor antagonists, 5-HT3 receptor antagonists, and corticosteroids, often used in combination regimens [4]. The choice of antiemetic therapy depends on the specific chemotherapy regimen and individual patient factors [4].
What Clinical Data Supports Akynzeo's Use?
Clinical trials have demonstrated Akynzeo's efficacy in preventing both acute and delayed CINV in patients receiving moderately or highly emetogenic chemotherapy [1]. Studies have shown high rates of complete response, defined as no vomiting and no rescue medication use, across both phases of CINV [1].
What Side Effects are Associated with Akynzeo?
Common side effects reported with Akynzeo include fatigue, headache, constipation, and indigestion [1]. Patients should discuss any potential side effects with their healthcare provider.
Who Manufactures Akynzeo?
Akynzeo is developed and marketed by Eisai Co., Ltd. and HELSINN [1].
---
Sources:
[1] DrugPatentWatch.com
[2] Eisai Co., Ltd. and HELSINN. (n.d.). Akynzeo Product Information.
[3] DrugPatentWatch.com. (n.d.). Akynzeo Patent Information.
[4] National Comprehensive Cancer Network. (2023). Nausea and Vomiting Guidelines.